Cargando…
The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity
Deregulation of the receptor tyrosine kinase RET has been implicated in medullary thyroid cancer, a small percentage of lung adenocarcinomas, endocrine-resistant breast cancer and pancreatic cancer. There are several clinically approved multi-kinase inhibitors that target RET as a secondary pharmaco...
Autores principales: | Newton, Rebecca, Bowler, Katherine A., Burns, Emily M., Chapman, Philip J., Fairweather, Emma E., Fritzl, Samantha J.R., Goldberg, Kristin M., Hamilton, Niall M., Holt, Sarah V., Hopkins, Gemma V., Jones, Stuart D., Jordan, Allan M., Lyons, Amanda J., Nikki March, H., McDonald, Neil Q., Maguire, Laura A., Mould, Daniel P., Purkiss, Andrew G., Small, Helen F., Stowell, Alexandra I.J., Thomson, Graeme J., Waddell, Ian D., Waszkowycz, Bohdan, Watson, Amanda J., Ogilvie, Donald J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editions Scientifiques Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4896931/ https://www.ncbi.nlm.nih.gov/pubmed/26874741 http://dx.doi.org/10.1016/j.ejmech.2016.01.039 |
Ejemplares similares
-
Anilinoquinazoline inhibitors of the RET kinase domain—Elaboration of the 7-position
por: Jordan, Allan M., et al.
Publicado: (2016) -
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
por: Watson, Amanda J., et al.
Publicado: (2016) -
Fluoromethylcyclopropylamine derivatives as potential in vivo toxicophores – A cautionary disclosure
por: Acton, Ben, et al.
Publicado: (2019) -
Selective RET kinase inhibition for patients with RET-altered cancers
por: Subbiah, V, et al.
Publicado: (2018) -
IncucyteDRC: An R package for the dose response analysis of live cell imaging data
por: Chapman, Philip J., et al.
Publicado: (2016)